The Latest Breaking News from Moderna

Tesla bounced early after leading a growth sell-off with Moderna and Nvidia. Many industrial and energy plays are thriving

Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth, the industry prospects look bright. Therefore, investors looking to invest in biotech stocks could consider buying Biogen (BIIB) and Jazz…

A world-first melanoma vaccine which personalises treatments for patients may put an end to melanoma as a "death sentence", according to Australian experts.

Jab led to reduction in risk of cancer coming back or death in patients with stage three and four melanoma

Moderna has partnered with another drug company to produce a personalised vaccine against melanoma for people at risk of dying.

A Relative Strength Rating upgrade for Moderna stock shows improving technical performance.

Moderna and Merck team up in new study.

The Dow Jones moved higher. Tesla CEO Elon Musk lost a famous title. Bitcoin rose after the Sam Bankman-Fried arrest. Moderna stock jumped.

Thank you, science.